BNTX
BioNTech SE
$91.17
+2.20% 2026-10-20
Healthcare
BNTXSPY
1W
+2.4%
1M
-5.1%
3M
-1.3%
6M
-18.3%
YTD
-4.2%
1Y
-15.5%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsBioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
GlobeNewswire · 15h ago
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
Zacks · Oct 19
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
GlobeNewswire · Oct 19
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Motley Fool · Oct 18
Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX)
Simply Wall St. · Oct 17
Key stats
Market cap$22.9B
P/E (trailing)–
P/E (forward)-16.9
52-week range79.52 – 124.00
Revenue growth (YoY, latest qtr)-59.5%
Dividend yield0.00%
Analyst consensusBuy (20)
Mean price target$116.99 (+28%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-03 · before open · EPS est 0.76
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | -2.08 | -2.22 | -6.8% |
| 2026-05-05 | -1.92 | -1.95 | -1.6% |
| 2026-03-10 | -0.25 | -0.33 | -30.4% |
| 2025-11-03 | 0.10 | -0.12 | -220.3% |
| 2025-08-04 | -1.41 | -1.60 | -13.8% |
| 2025-05-05 | -2.35 | -1.73 | +26.3% |
| 2025-03-10 | 0.37 | 1.08 | +188.9% |
| 2024-11-04 | -1.61 | 0.81 | +150.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $105.6M | -59.5% |
| 2026-03-31 | $118.1M | – |
| 2025-12-31 | $907.4M | – |
| 2025-09-30 | $1.5B | – |
| 2025-06-30 | $260.8M | – |
Analyst actions
Canaccord Genuity
PT $132
2026-10-14 · main
Buy → BuyPT $132
Morgan Stanley
PT $114
2026-10-07 · main
Overweight → OverweightPT $114
BMO Capital
PT $105
2026-09-08 · down
Outperform → Market PerformPT $105
Canaccord Genuity
PT $136
2026-08-31 · main
Buy → BuyPT $136
Citigroup
PT $125
2026-08-05 · main
Buy → BuyPT $125
Evercore ISI Group
PT $130
2026-08-05 · main
Outperform → OutperformPT $130
Recent dividends
2022-06-02: $2.111
Insider trades
Sahin Ugur
$3.5M
Chief Executive Officer, 10% owner · 2026-10-09
SELL$3.5M
Sahin Ugur
$2.5M
Chief Executive Officer, 10% owner · 2026-10-08
SELL$2.5M
Sahin Ugur
$2.3M
Chief Executive Officer, 10% owner · 2026-10-07
SELL$2.3M
Sahin Ugur
$2.0M
Chief Executive Officer, 10% owner · 2026-10-06
SELL$2.0M
Sahin Ugur
$7.0M
Chief Executive Officer, 10% owner · 2026-10-05
SELL$7.0M
Sahin Ugur
$1.6M
Chief Executive Officer, 10% owner · 2026-10-02
SELL$1.6M
Sahin Ugur
$1.7M
Chief Executive Officer, 10% owner · 2026-10-01
SELL$1.7M
Sahin Ugur
$3.1M
Chief Executive Officer, 10% owner · 2026-09-30
SELL$3.1M
Sahin Ugur
$3.3M
Chief Executive Officer, 10% owner · 2026-09-29
SELL$3.3M
Sahin Ugur
$3.3M
Chief Executive Officer, 10% owner · 2026-09-28
SELL$3.3M
Sahin Ugur
$2.7M
Chief Executive Officer, 10% owner · 2026-09-25
SELL$2.7M
Sahin Ugur
$3.9M
Chief Executive Officer, 10% owner · 2026-09-24
SELL$3.9M
Stats refreshed 2026-10-20 18:13:54 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteauCoteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.